Literature DB >> 10722861

Neural and humoral mechanisms mediating cardiovascular responses to obstructive sleep apnea.

B G Phillips1, V K Somers.   

Abstract

Patients with obstructive sleep apnea are at increased risk for hypertension. The mechanisms underlying this increased risk are not known. During sleep, repetitive apneic episodes result in hypoxemia and carbon dioxide retention, which cause increases in sympathetic nerve activity and elicit humoral vasoconstrictor responses. While these mechanisms explain nocturnal elevations in blood pressure, it is unclear why hypertension and elevated sympathetic nerve activity prevail even during the daytime. This review will examine briefly some of the neural and humoral mechanisms that are activated by nocturnal apneas and which may contribute to persistent increases in blood pressure even during daytime normoxia. Disruption of the autonomic and hemodynamic profile of normal sleep by apneic events manifests as raised blood pressure and heightened sympathetic nerve traffic during sleep. During awake daytime normoxia, baroreflex and chemoreflex dysfunction may contribute to maintenance of higher blood pressure and sympathetic activity. Sustained vasoconstrictor effects of nocturnal endothelin release may also be implicated in the elevated daytime blood pressures.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722861     DOI: 10.1016/s0034-5687(99)00113-9

Source DB:  PubMed          Journal:  Respir Physiol        ISSN: 0034-5687


  12 in total

Review 1.  Morbidity of obstructive sleep apnea in children: facts and theory.

Authors:  D Gozal
Journal:  Sleep Breath       Date:  2001       Impact factor: 2.816

Review 2.  Sleep.7: positive airway pressure therapy for obstructive sleep apnoea/hypopnoea syndrome.

Authors:  P Gordon; M H Sanders
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

3.  Investigation of pulse transit time characteristics during single and recurrent obstructive respiratory events.

Authors:  Jong Yong A Foo; Stephen J Wilson; Gordon R Williams; Margaret-Ann Harris; David M Cooper
Journal:  J Clin Monit Comput       Date:  2008-08-21       Impact factor: 2.502

4.  Chronic intermittent hypoxia induces hypoxia-evoked catecholamine efflux in adult rat adrenal medulla via oxidative stress.

Authors:  Ganesh K Kumar; Vandana Rai; Suresh D Sharma; Devi Prasadh Ramakrishnan; Ying-Jie Peng; Dangjai Souvannakitti; Nanduri R Prabhakar
Journal:  J Physiol       Date:  2006-06-15       Impact factor: 5.182

Review 5.  Integrated Cardio-Respiratory Control: Insight in Diabetes.

Authors:  Luciano Bernardi; Lucio Bianchi
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

6.  C-reactive protein and carotid intima-media thickness in children with sleep disordered breathing.

Authors:  Arcangelo Iannuzzi; Maria Rosaria Licenziati; Fausto De Michele; Maria Carmela Verga; Carlo Santoriello; Luigi Di Buono; Maurizio Renis; Loredana Lembo; Bruno D'Agostino; Donato Cappetta; Mario Polverino; Francesca Polverino
Journal:  J Clin Sleep Med       Date:  2013-05-15       Impact factor: 4.062

Review 7.  Post-translational modification of proteins during intermittent hypoxia.

Authors:  Ganesh K Kumar; Nanduri R Prabhakar
Journal:  Respir Physiol Neurobiol       Date:  2008-12-10       Impact factor: 1.931

8.  OSA and atherosclerosis.

Authors:  Macy Mei-Sze Lui; Mary Sau-Man
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

9.  Increased secretory capacity of mouse adrenal chromaffin cells by chronic intermittent hypoxia: involvement of protein kinase C.

Authors:  Barbara A Kuri; Shakil A Khan; Shyue-An Chan; Nanduri R Prabhakar; Corey B Smith
Journal:  J Physiol       Date:  2007-08-16       Impact factor: 5.182

10.  Endothelin type A receptor antagonist normalizes blood pressure in rats exposed to eucapnic intermittent hypoxia.

Authors:  Kyan J Allahdadi; Tom W Cherng; Hemanth Pai; Ana Q Silva; Benjimen R Walker; Leif D Nelin; Nancy L Kanagy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-30       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.